The Impact of PPAR𝜸 Genetic Variants on IBD Susceptibility and IBD Disease Course

Table 5

Number of variant carriers (12333125A>G and 12415557C>T) in CD and UC patients compared to controls.

Category				12333125A>G
	Genotype	N ^(a)	N (%) of SNP carriers	OR (C.I.)	𝑃^(c)	OR (C.I)^(b)	𝑃^(b)
CD	Het plus hom	143	28 (19.6)	0.68 (0.40–1–15)	0.15^(d)	0.67 (0.40–1.14)	0.14
control	Het plus hom	182	48 (26.4)
CD	hom	116	1 (0.9)	0.58 (0.05–6.51)	1.0	0.77 (0.23–2.61)	0.68
control	hom	136	2 (1.5)
UC	Het plus hom	140	30 (21.4)	0.76 (0.45–1.28)	0.31^(d)	0.78 (0.46–1.32)	0.35
control	Het plus hom	182	48 (26.4)
UC	hom	111	1 (0.9)	0.61 (0.06–6.81)	1.0	0.70 (0.21–2.38)	0.57
control	hom	136	2 (1.5)
				12415557C>T
CD	Het plus hom	139	31 (22.3)	0.91 (0.54–1.54)	0.72^(d)	0.92 (0.54–1.56)	0.74
control	Het plus hom	175	42 (24.0)
CD	hom	109	1 (0.9)	0.31 (0.03–2.80)	0.39	0.54 (0.18–1.62)	0.27
control	hom	137	4 (2.9)
UC	Het plus hom	134	32 (23.9)	0.99 (0.59–1.68)	0.98^(d)	0.94 (0.55–1.62)	0.83
control	Het plus hom	175	42 (24.0)
UC	hom	104	2 (1.9)	0.65 (0.12–3.63)	0.70	0.84 (0.35–1.99)	0.69
control	hom	137	4 (2.9)

OR: odds ratio; CI: confidence interval; N: absolute number; het: heterozygous; hom: homozygous; ^(a) absolute number of all patients of the respective subgroup included into the analysis; ^(b) adjusted for age and sex; ^(c)𝑃 values calculated with Fisher’s exact test; ^(d)𝑃 value calculated with Chi-Square test.